FOXO4-DRI
A senolytic peptide designed to target and eliminate senescent ('zombie') cells to rejuvenate tissues.
Common Dosage
Experimental/Research only
Category
Longevity
- Senolysis (clearing aged cells)
- Tissue rejuvenation
FOXO4-DRI was developed by Peter de Keizer and colleagues at Utrecht University and published in Cell in 2017 in a paper that made headlines worldwide. The peptide is a D-amino acid retro-inverso version of a FOXO4 peptide domain that disrupts the interaction between FOXO4 and p53 in senescent cells. The Cell paper showed that injecting FOXO4-DRI into fast-aged or naturally old mice restored fur density, kidney function, and physical fitness within weeks — results that were visually dramatic and scientifically significant.
Senescent ('zombie') cells accumulate with age and following cellular stress, persisting in tissues due to enhanced survival pathways. In senescent cells, FOXO4 interacts with p53 and sequesters it in the nucleus, preventing the cell from triggering apoptosis. FOXO4-DRI is a competitive inhibitor of this FOXO4-p53 interaction, releasing p53 to trigger mitochondria-dependent apoptosis selectively in senescent cells — which have higher FOXO4 nuclear expression than normal cells. Normal cells are largely spared because they lack this FOXO4-mediated survival dependency.
- Senolytic therapy — clearing senescent cell burden
- Age-related tissue rejuvenation
- Cancer treatment recovery — clearing chemotherapy-induced senescent cells
- Frailty and physical decline in aging
- Organ function restoration research
Landmark Cell 2017 Study
The de Keizer et al. 2017 study demonstrated that FOXO4-DRI injections in fast-aged mice (through chemotherapy-induced senescence) and naturally old mice showed restoration of physical activity, fur density, and kidney function within weeks — with histological evidence of senescent cell clearance. The results were considered a proof-of-concept for targeted senolytics.
Alopecia Research
Subsequent data from the de Keizer group showed that FOXO4-DRI restored hair density in chemotherapy-induced alopecia — a significant quality-of-life application that attracted attention from oncology communities.
- Human clinical trials have not yet been completed — efficacy and safety in humans are not established
- Senolysis produces a significant inflammatory 'burst' as cleared cells release their contents — the fatigue and malaise reported during FOXO4-DRI protocols may be dose-limiting for some users
- Excessive senolytic activity could theoretically impair beneficial roles of senescent cells in wound healing and tumor suppression
- D-amino acid peptides are resistant to proteolytic degradation — longer tissue persistence compared to L-peptides is pharmacokinetically relevant
- The research peptide market for this compound has limited quality standards
- Fatigue during clearing phase